Here's why I added Resmed shares to my portfolio last week

Fear is consuming the Resmed share price. I've decided to take action while the market is panicking.

| More on:
A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In less than two months, Resmed Inc (ASX: RMD) shares have cascaded 35.7% to their lowest price since March 2020.

The violent hit to the medical device company comes amid mounting fears of market disruption caused by glucagon-like peptide 1 (GLP-1) drugs.

Going against the grain, I decided to buy Resmed shares last week. In this article, I'll explain why I think the market is being irrational and how Resmed could still succeed in this evolving landscape.

Shoot first, ask questions later

Known more commonly by their label names, such as Wegovy and Mounjaro, weight-loss medications are creating a ruckus in the healthcare industry. The fear is that GLP-1s could uproot existing indirect treatments due to the prevalent link between an array of health issues and obesity.

It's a classic example of root cause analysis: addressing the source of the problem rather than trying to treat the symptoms.

Resmed is a big player in treating obstructive sleep apnea (OSA) — a sleep disorder believed to affect 20% of the global population. It is commonly cited that obesity is considered one of the main risk factors for sleep apnea, with estimates indicating roughly 70% of OSA sufferers are obese.

Investors are worried that these new medications could usurp Resmed by solving the underlying cause of the disorder it treats, hurting Resmed shares. While the jury is still out on the substantive evidence, it appears shareholders are not waiting around to find out.

Three reasons why I think GLP-1s won't eat Resmed's lunch

I want to provide three clear-cut points for why I added Resmed to my portfolio.

  1. Early evidence for reduced sleep apnea from GLP-1 use is combined with exercise and a restrictive diet. This may suggest that sleep apnea issues could persist without lifestyle changes.
  2. If GLP-1s do disrupt the OSA industry, the market opportunity remains significant. An estimated ~485 million people with sleep apnea are not exposed to obesity — Resmed currently serves around 160 million.
  3. Weight-loss medications and continuous positive airway pressure machines (CPAP) — the devices Resmed sells — could be complementary.

Homing in on that last point. The real winners from this are the people who suffer from sleep apnea. It may give people more choice. Studies show that some people don't stick with CPAP machines… likewise, others don't gel with these new medications.

I think investors are forgetting that different solutions can co-exist in large markets.

Pulling the trigger on Resmed shares

I have long admired Resmed as a company. The ability to constantly innovate on its devices, expand its market share, and maintain commendable margins.

However, during my time as an investor, the Resmed shares price has usually traded on a price-to-earnings (P/E) ratio of between 30 and 50 times. I couldn't stomach the premium price. A mistake in hindsight.

The market's recent irrationality, in my opinion, has given me a second chance. Now, Resmed trades at 24 times earnings.

Still conscious of the risks, I have added a modest position with the intention to add more in the future. Right now, Resmed shares make up 2.7% of my personal portfolio.

Motley Fool contributor Mitchell Lawler has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.

It's up 3,500%, but here's why I'm still not buying Nvidia stock

I wish I bought Nvidia in 2023, but I'm not buying it in 2024.

Read more »

kid riding a plastic go kart with his hands raised in the air with mountains in the background symbolising winning a race

Down 15% in 4 months, is it time to buy this ASX growth stock?

I think this ASX growth stock is a great performer.

Read more »

A man in a supermarket strikes an unlikely pose while pushing a trolley, lifting both legs sideways off the ground and looking mildly rattled with a wide-mouthed expression.
Consumer Staples & Discretionary Shares

The Woolworths share price is down 16%: Time to buy the stock?

I think now looks like a good time to put this supermarket stock in the shopping basket.

Read more »

a man peers through a broken brick wall to see grey clouds gathering beyond it

Are Brickworks shares about to benefit from an industrial property boom?

Brickworks shares can be a cheaper way to gain exposure, in my view.

Read more »

A woman throws her hands in the air in celebration as confetti floats down around her, standing in front of a deep yellow wall.

Would I be crazy to buy Guzman y Gomez (GYG) shares at $30?

The GYG share price had a stunning start on the ASX. Has it gone too high?

Read more »

Woman with a floatable flamingo at a beach, symbolising passive income.
Dividend Investing

3 top ASX 200 stocks that could create lasting passive income into retirement

Passive income investors have a number of top ASX 200 shares to choose from. Here’s why I like these three.

Read more »

Three young people in business attire sit around a desk and discuss.

3 of the best growth-focused ASX shares to buy in June

Looking for growth stocks to invest in? I think these three ASX growth shares have the potential for a bright…

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.

Bull market buys: 1 magnificent ASX stock to own for the long run

I think paying a premium for quality stocks can pay off in the long term.

Read more »